SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GenVec - GNVC
GNVC 7.1930.0%Jun 26 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Savant12/6/2010 9:41:07 AM
   of 106
 
GenVec says data were presented on respiratory syncytial virus vaccine program at the International Respiratory Syncytial Virus Symposium; demonstrated encouraging preclinical proof-of-concept findings generated in multiple animal models at the NIH and GenVec
Co announces data were presented on respiratory syncytial virus vaccine program. Data presented demonstrated encouraging preclinical proof-of-concept findings generated in multiple animal models at the NIH and GenVec. Specifically, the data show sustained production of neutralizing antibodies and the lack of immunological responses associated with adverse events linked to prior unsuccessful RSV vaccine approaches.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News